Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
SanBio Co ( (JP:4592) ) just unveiled an announcement.
SanBio Co., Ltd. announced that the Subcommittee on Regenerative Medical Products and Biological Technologies has deemed the partial change proposal for AKUUGO acceptable, paving the way for its launch after NHI price listing. AKUUGO, the world’s first regenerative brain therapy, received conditional approval in Japan in 2024, and SanBio plans to expand its traumatic brain injury program to the U.S. market, aiming to become a leader in regenerative medicine.
The most recent analyst rating on (JP:4592) stock is a Sell with a Yen1010.00 price target. To see the full list of analyst forecasts on SanBio Co stock, see the JP:4592 Stock Forecast page.
More about SanBio Co
SanBio Co., Ltd. is a company in the regenerative medicine industry, focusing on developing innovative therapies for neurological conditions. Their primary product, AKUUGO, is a regenerative therapy for the brain, specifically targeting chronic motor paralysis due to traumatic brain injury.
Average Trading Volume: 2,506,191
Technical Sentiment Signal: Buy
Current Market Cap: Yen266.1B
Find detailed analytics on 4592 stock on TipRanks’ Stock Analysis page.